2. Respiratory System Flashcards

1
Q

What characterises asthma?

A

-Reversible airflow obstruction
-Airway inflammation
-Airway hyperresponsiveness

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What is obstruction in asthma caused by?

A

-Smooth muscle contraction
-Inflammation
-Oedema
-Mucous
-Airway structural changes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What are the main symptoms of asthma?

A

-Wheezing
-Chest tightness
-Dyspnea
-Cough
-Hypoxemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Describe airway inflammation in asthma

A

-Eosinophils, mast cells, T-helper 2 (Th2) lymphocytes, and neutrophils infiltrate the airway walls
-Increased vascular permeability leads to swelling of the airway walls, forming oedema
-Goblet cell hyperplasia and submucosal gland hypertrophy lead to excessive mucus production
-Constriction in smooth muscle

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Describe airway remodelling in asthma

A

-Subepithelial fibrosis reduces elasticity
-Epithelial damage may exacerbate hyperresponsiveness
-Smooth muscle hypertrophy and hyperplasia leads to thicker walls

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Describe the immediate acute phase of asthma

A

-Eliciting agent of allergen or non specific stimulus
-Increases activity of mast cells (releasing spasmogens and chemokines/taxins)
-Spasmogens lead to bronchospasm

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Describe the late acute phase of asthma

A

-Infiltration of chemokine/taxins leads to infiltration of cytokine TH2 cells and monocytes AND activation of inflammatory cells such as eosinophils
-Leads to mediators eg CysLTs, neuropeptides, NO, that contribute to airway inflammation and airway hypereactivity
-Also leads to EMBP and ECP release, leading to hyperreactivity
-These contribute to bronchospasm, wheezing and cough

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Describe features the chronic phase of asthma

A

-Persistant inflammation
-Airway remodelling
-Airway hyperresponsiveness
-Obstruction and reduced lung function

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Describe β2 adrenoceptor agonists as treatments for asthma

A

-Cause relaxation of airway smooth muscle by increasing cAMP through Gs physiological antagonists to bronchoconstrictors
-Either short or long acting β2 agonists
-Less systemic effects as most are directly inhaled

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Give examples of β2 adrenoceptor agonists used to treat asthma

A

-Adrenaline: Non-selective ⍺, β1 and β2 effects
-Isoprenaline (isoproterenol): Selective β agonist, leading to bronchodilation and cardiac stimulation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Describe short acting β2 agonists used to treat asthma, and give examples

A

-Use as needed for acute episodes
-Inhaled, with relief within 5-10 minutes, with max effect within 30 minutes
-Duration lasts 3-5 hours
-eg Salbutamol, terbutaline

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Describe longer acting β2 agonists used to treat asthma, and give examples

A

-Given regularly twice daily, slow onset so not appropriate for an acute episode
-12 hour duration
-Used as an adjunct to corticosteroids
-eg Salmeterol, formoterol

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Give routes of administration for β2 agonists used to treat asthma

A

-Aerosol inhalation - metered-dose inhaler
-Inhalation of nebulised solution
-Inhalation of powder
-Oral (tablet or solution) administration
-Parenteral → IV, SC or IM injection

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Give side effects associated with β2 agonists used to treat asthma

A

-Side effects are minimised with delivery via inhalation, but the following may occur:
-Muscle tremor at high doses
-Tachycardia
-Cardiac dysrhythmias
-Risk of paradoxical bronchospasm

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What is SRS-A?

A

-Slow reacting substance of anaphylaxis
-Comprised of LTC₄ (Leukotriene C₄), LTD₄ (Leukotriene D₄), LTE₄ (Leukotriene E₄)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Describe the production of SRS-A compounds

A

-Activation of mast cells triggers arachidonic acid release
-5-lipoxygenase metabolizes arachidonic acid into LTC₄, which is then converted to LTD₄ and LTE₄.

17
Q

Describe the action of SRS-A compounds in asthma

A

-Potent constrictors of bronchial smooth muscle
-Increase vascular leakage, mucus production
-Chemoattractants for eosinophils/basophils

18
Q

Describe targets for therapies for asthma targeting SRS-A/Leukotrienes

A

-Conversion of Arachidonic acid to Leukotrienes: Inhibitors of 5-lipoxygenase
-Binding of leukotrienes to Cys-LT1 receptors: Leukotriene receptor antagonists

19
Q

Give a 5-lipoxygenase inhibitor

20
Q

Give some leukotriene receptor antagonists

A

-Zafirlukast
-Montelukast

21
Q

Describe some issues with leukotriene modulators

A

-Weak anti inflammatory effects
-Weak bronchodilator
-Used in mild to moderate asthma: improve basal lung function and symptoms; indicated as
alternative to low dose ICS and/or add-on therapy

22
Q

What may cause differences in responders vs non responders to leukotriene modulators?

A

May be due to polymorphisms in 5LOX, LTC4 synthase or CysLT1 receptors

23
Q

Describe treatment of asthma with antimuscarinics

A

-Muscarinic (M3) receptor antagonist leads to bronchodilation and reduces mucous secretion
-Used as adjunct therapy to b2 agonists and steroids
-May increase mucociliary clearance through action on cilia of epithelial cell
-Main use in COPD

24
Q

Describe SAMAs used to treat asthma

A

-Short acting Muscarinic antagonists
-Primarily used for acute symptom relief during an asthma attack or exacerbation.
-Often used as rescue inhalers.
-Slower onset (30-60 minutes)
-eg Ipratropium bromide

25
Q

Describe LAMAs used to treat asthma

A

-Longer acting Muscarinic antagonists
-Primarily used for maintenance treatment of asthma, especially in moderate to severe asthma.
-Long-lasting effects, usually up to 24 hours.
-Slower onset >1 hour
-eg Tiotropium bromide

26
Q

What are the side effects associated with SAMA and LAMAs for asthma?

A

Typical anticholinergic side effects

27
Q

Describe glucocorticoids used to treat asthma

A

-Inhibit inflammatory response to injury and allergic disease
-Inhibit synthesis of inflammatory mediators, cytokines, cell chemoattractants, vasoactive agents
-Decrease inflammatory cell infiltration and proliferation, vascular permeability and mucus secretion

28
Q

Describe inhaled corticosteroids used to treat asthma

A

-Effective in controlling chronic inflammation.
-Help reduce asthma symptoms (wheezing, coughing, shortness of breath).
-Reduces transcription and decreased formation of cytokines
-Preventative measure for exacerbations and hospitalizations.
-Minimal systemic side effects when used properly (low doses, correct inhalation technique).
-May up regulate β2 receptor expression

29
Q

Give some adverse effects associated with inhaled corticosteroids for asthma

A

-Oropharyngeal candidiasis may occur, with spacers helping to prevent
-Inhaled corticosteroid show reduced systemic side effects but may still cause adrenal suppression and reduced bone mineral density when taken long term

30
Q

Give examples of inhaled corticosteroids for asthma

A

-Beclometasone
-Budesonide

31
Q

Describe oral corticosteroids used to treat asthma

A

-Fast-acting for controlling severe inflammation.
-Used in the management of acute asthma exacerbations or when ICS are not adequate

32
Q

Give some adverse effects associated with oral corticosteroids for asthma

A

Prolonged corticosteroid therapy causes:
-Suppression of immune response to infection
-Cushing’s syndrome
-Osteoporosis
-Hyperglycaemia
-Muscle wasting
-Inhibition of growth in children

33
Q

Describe IL5 blockers used in asthma

A

-Mepolizumab is a monoclonal antibody that binds to IL-5 and prevents it from interacting with its receptor on eosinophils.